Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKinsey
Fuji
Deloitte
Colorcon
Dow
Healthtrust
Daiichi Sankyo
Chubb

Generated: October 17, 2017

DrugPatentWatch Database Preview

SEBELA IRELAND LTD Company Profile

« Back to Dashboard

What is the competitive landscape for SEBELA IRELAND LTD, and what generic alternatives to SEBELA IRELAND LTD drugs are available?

SEBELA IRELAND LTD has seventeen approved drugs.

There are eleven US patents protecting SEBELA IRELAND LTD drugs.

There are one hundred and fourteen patent family members on SEBELA IRELAND LTD drugs in thirty-nine countries and two supplementary protection certificates in two countries.

Summary for Applicant: SEBELA IRELAND LTD

International Patents:114
US Patents:11
Tradenames:12
Ingredients:10
NDAs:17
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sebela Ireland Ltd
NAFTIN
naftifine hydrochloride
GEL;TOPICAL019356-001Jun 18, 1990RXYesYes► Subscribe► Subscribe► Subscribe
Sebela Ireland Ltd
BRISDELLE
paroxetine mesylate
CAPSULE;ORAL204516-001Jun 28, 2013ABRXYesYes► Subscribe► SubscribeYY ► Subscribe
Sebela Ireland Ltd
ONMEL
itraconazole
TABLET;ORAL022484-001Apr 29, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Sebela Ireland Ltd
PEXEVA
paroxetine mesylate
TABLET;ORAL021299-004Jul 3, 2003RXYesYes► Subscribe► Subscribe ► Subscribe
Sebela Ireland Ltd
LOTRONEX
alosetron hydrochloride
TABLET;ORAL021107-001Feb 9, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe
Sebela Ireland Ltd
RIDAURA
auranofin
CAPSULE;ORAL018689-001May 24, 1985RXYesYes► Subscribe► Subscribe► Subscribe
Sebela Ireland Ltd
NAFTIN
naftifine hydrochloride
GEL;TOPICAL204286-001Jun 27, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Sebela Ireland Ltd
BRISDELLE
paroxetine mesylate
CAPSULE;ORAL204516-001Jun 28, 2013ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Sebela Ireland Ltd
MICORT-HC
hydrocortisone acetate
CREAM;TOPICAL040396-001Feb 27, 2001RXNoNo► Subscribe► Subscribe► Subscribe
Sebela Ireland Ltd
BRISDELLE
paroxetine mesylate
CAPSULE;ORAL204516-001Jun 28, 2013ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sebela Ireland Ltd

Paragraph IV activity for SEBELA IRELAND LTD drugs

Drugname Dosage Strength Tradename Submissiondate
paroxetine
Capsules7.5 mg
BRISDELLE
4/7/2014
alosetron hydrochloride
Tablets0.5 mg and 1 mg
LOTRONEX
12/2/2010

Non-Orange Book Patents for Sebela Ireland Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,433,680Topical compositions and methods for making and using same► Subscribe
6,900,327 4-phenylpiperidine compounds► Subscribe
9,149,431Itraconazole compositions with improved bioavailability► Subscribe
8,859,576Method of treating thermoregulatory dysfunction with paroxetine► Subscribe
9,446,131Topical compositions and methods for making and using same► Subscribe
9,452,173Topical compositions and methods for making and using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sebela Ireland Ltd Drugs

Country Document Number Estimated Expiration
South Africa9704338► Subscribe
China1209740► Subscribe
Mexico9805418► Subscribe
Denmark0994872► Subscribe
Bulgaria103980► Subscribe
Germany69726729► Subscribe
Portugal994872► Subscribe
Poland188450► Subscribe
Japan5846717► Subscribe
New Zealand330739► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sebela Ireland Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Mallinckrodt
Citi
Johnson and Johnson
Accenture
US Department of Justice
Fuji
Argus Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot